Alembic Pharmaceuticals has received final approval from the US Food & Drug Administration (USFDA) for its abbreviated new drug application (ANDA) Vardenafil Hydrochloride Tablets, 2.5 mg (base), 5 mg (base), 10 mg (base), and 20 mg (base).
The approved ANDA is therapeutically equivalent to the reference listed drug product, Levitra tablets, 2.5 mg, 5 mg, 10 mg, and 20 mg, of Bayer Healthcare Pharmaceuticals.
Also read: Sun Pharma launches Favipiravir in India at Rs 35 per tablet
Vardenafil Hydrochloride Tablets are indicated for the treatment of erectile dysfunction. They have an estimated market size of $35 million for twelve months ending June 2020 according to IQVIA.
Alembic now has a total of 127 ANDA approvals (112 final approvals and 15 tentative approvals) from USFDA.
The Health Master is now on Telegram. For latest update on health and Pharmaceuticals, subscribe to The Health Master on Telegram.
